Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and ...

Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022

Related Keywords

Japan ,Canada ,United States ,America ,David Schull ,Richardj Daly ,Mary Coleman ,Dydo Pharma Inc ,Catalyst Pharmaceuticals Inc ,Catalyst Or Company Nasdaq ,Drug Application To Japan Pharmaceuticals ,Mcap Companies ,Devices Agency ,Health Canada ,International Number ,Exchange Commission On ,Achieved Record ,Increase Compared ,Record Fourth Quarter ,Fourth Quarter ,Neuroscience Commercial Portfolio ,Revenues Guidance ,Year Ended December ,Net Product ,Income Per Share ,Full Year ,Steven Miller ,Executive Vice President ,Chief Operating ,Scientific Officer ,Jeffrey Del Carmen ,Chief Commercial Officer ,Michael Kalb ,Chief Financial ,Dydo Pharma ,New Drug Application ,Medical Devices Agency ,Most Successful Small Cap ,Annual Epilepsy Awareness ,Annual Report ,Exchange Commission ,Canada Dial In Number ,Dial In Number ,Catalyst Pharmaceuticals ,North America ,Duchenne Muscular ,Fast Track ,Full Prescribing ,Safety Information ,Full Prescribing Information ,Three Months ,Investor Contact Mary Coleman ,Contact David Schull ,Russo Partners ,